Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>BofAS Cuts TP for CSPC PHARMA (01093.HK) to HKD8, Rating Underperform
Recommend 4 Positive 4 Negative 3 |
||||
|
||||
|
CSPC PHARMA (01093.HK) booked a total revenue of RMB26 billion in 2025, a YoY drop of 10.4%, and a net profit of RMB3.9 billion, a YoY fall of 10.3%, BofA Securities said in its report. The broker expected CSPC Pharmaceutical's total collaboration revenue to exceed RMB10 billion in 2026 and adjusted its revenue forecasts from 2026 to 2028, with increase of 0.4% and decrease of 4.1% and decrease of 4.1%, respectively. The EPS forecasts for 2026-28 were revised down by 0.4%, 7.1%, and 22.3%. Its target price was lowered from HKD9.1 to HKD8, with rating Underperform kept. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
